Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 2;129(6):669–683. doi: 10.1161/CIRCRESAHA.120.318577

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors.

Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 6. — GAS5 (growth arrest-specific 5) overexpression reduces hypertrophy in SRSF4 (serine/arginine splicing factor 4) KO cardiomyocytes.A–D, Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of the hypertrophy markers ANF and brain natriuretic peptide (BNP) (A and B) and the GR (glucocorticoid receptor) targets Fkbp5 and Gliz (C and D) in control and SRSF4 KO neonatal cardiomyocytes treated with 100 nmol/L DEX and transfected with GAS5 or control modRNA. Data are shown as mean±SEM, and symbols represent 3 independent experiments (biological replicates), each of them the average of 2 (control) or 3 (KO) technical replicates. In each independent experiment, values were normalized to the mean value of control samples with no DEX and no GAS5 in each genotype (dotted line). *P<0.05 GAS5 vs control modRNA; 2-way ANOVA followed by the Bonferroni posttest. E, Area of control and SRSF4 KO neonatal cardiomyocytes treated with 100 nm DEX and transfected with GAS5 or control modRNA. Data are shown as mean±SEM, and symbols represent the average of individual cardiomyocytes in each biological replicate. **P<0.01, GAS5 vs control modRNA; 2-way ANOVA followed by the Bonferroni posttest.